Opinion

Video

Therapeutic Response and Disease Progression

Author(s):

Justin Oldham, MD, MS

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Video content above is prompted by the following:

  1. How can multidisciplinary care be optimized when treating patients with IPF?
  2. Describe the therapeutic response and disease progression of patients taking standard of care therapies (pharmacologic and non-pharmacologic).
Related Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
2 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Related Content
Hospital exterior | Image Credit: Spiroview Inc. - stock.adobe.com
May 16th 2025

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

Brooke McCormick
Facility-level disparities in adopting minimally invasive interval debulking surgery for ovarian cancer highlight urgent needs for equitable care access.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
AJMC
May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD
This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Transplant-free survival from the time of right-heart catheterization was also significantly longer in the dual therapy group. | Image Credit: mi_viri - stock.adobe.com
May 15th 2025

Dual Therapy Appears to Benefit Patients With Pulmonary Fibrosis, Pulmonary Hypertension

Jared Kaltwasser
The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.
Heartbeat EKG | Image Credit: © Tima-stock.adobe.com
May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

Maggie L. Shaw
Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo